ArticleApoptosis : an international journal on programmed cell death2025
FOXP2/SOS1/AKT negative feedback loop inhibits cell proliferation in KRAS-mutant colorectal cancer.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
FOXP2, a member of the Forkhead box transcription factor family, has been implicated in diverse biological processes and malignancies. However, its role in colorectal cancer (CRC), particularly in the context of KRAS mutations, remains poorly defined. Here, we analyzed FOXP2 expression in CRC datasets and clinical specimens, and conducted functional assays-including colony formation, cell viability, EdU incorporation, and cell cycle analysis-in KRAS-mutant CRC cell lines with FOXP2 overexpression or knockdown. Western blotting, dual-luciferase reporter assays, and in vivo xenograft models were used to explore the underlying mechanisms. FOXP2 was significantly downregulated in CRC tissues and its high expression correlated with favorable prognosis in KRAS-mutant patients. Functionally, FOXP2 overexpression suppressed cell proliferation, induced G0/G1-phase arrest, and inhibited PI3K/AKT signaling. Mechanistically, FOXP2 transcriptionally repressed SOS1, thereby attenuating downstream AKT activation. Notably, AKT activation enhanced FOXP2 expression, indicating a FOXP2/SOS1/AKT negative feedback loop. Collectively, our findings suggest that FOXP2 inhibits proliferation in KRAS-mutant CRC by suppressing SOS1-mediated PI3K/AKT signaling, and may serve as a prognostic biomarker and potential therapeutic target in KRAS-driven CRC.
Indexed as
Identifiers
40813540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.